# TIAM2S Operates Multifaced Talents to Alleviate Radiosensitivity, Restrict Apoptosis, Provoke Cell Propagation, and Escalate Cell Migration for Aggravating Radioresistance-Intensified Cervical Cancer Progression

**Authors:** Pei-Chin Chuang, Wen-Hong Su, Ching-Hua Hsieh, Eng-Yen Huang

PMC · DOI: 10.3390/cells14050339 · 2025-02-26

## TL;DR

TIAM2S helps cervical cancer cells resist radiation by reducing cell death and increasing migration, suggesting it could be a new target for improving radiotherapy outcomes.

## Contribution

This study identifies TIAM2S as a novel factor in cervical cancer radioresistance, showing its role in radioprotection, apoptosis restriction, and metastasis promotion.

## Key findings

- TIAM2S is upregulated in radioresistant cervical cancer cells and reduces radiosensitivity and apoptosis.
- TIAM2S overexpression increases cell migration and metastasis in cervical cancer.
- Blocking TIAM2S reduces radioresistance and lung metastasis in a mouse model.

## Abstract

Radioresistance remains a major obstacle in cervical cancer treatment, frequently engendering tumor relapse and metastasis. However, the details of its mechanism of action remain largely enigmatic. This study delineates the prospective impacts of short-form human T-cell lymphoma invasion and metastasis 2 (TIAM2S) involving the radiation resistance of cervical cancer. In this study, we established three pairs of radioresistant (RR) cervical cancer cells (HeLa, C33A and CaSki) and their parental wild-type (WT) cells. We revealed a consistent augmentation of TIAM2S, but not long-form human T-cell lymphoma invasion and metastasis 2 (TIAM2L) were displayed in RR cells that underwent a 6 Gy radiation administration. Remarkably, RR cells exhibited decreased radiosensitivity and abridged apoptosis, as estimated through a clonogenic survival curve assay and Annexin V/Propidium Iodide apoptosis assay, respectively. TIAM2S suppression increased radiosensitivity and enhanced cell apoptosis in RR cells, whereas its forced introduction modestly abolished radiosensitivity and diminished WT cell apoptosis. Furthermore, TIAM2S overexpression notably aggravated RR cell migration, whereas its blockage reduced WT cell mobilities, as confirmed by an in vitro time-lapse recording assay. Notably, augmented lung localization was revealed after a tail-vein injection of CaSki-RR cells using the in vivo short-term lung locomotion BALB/c nude mouse model. TIAM2S impediment notably reduced radioresistance-increased lung locomotion. This study provides evidence that TIAM2S may operate as an innovative signature in cervical cancer that is resistant to radiotherapy. It displays multi-faceted roles including radioprotection, restricting apoptosis, promoting cell proliferation, and escalating cell migration/metastasis. Targeting TIAM2S, together with conventional radiotherapy, may be an innovative strategy for intensifying radiosensitivity and protecting against subsequent uncontrolled tumor growth and metastasis in cervical cancer treatment.

## Linked entities

- **Diseases:** cervical cancer (MONDO:0002974)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}
- **Diseases:** tumor (MESH:D009369), Cervical Cancer (MESH:D002583), metastasis (MESH:D009362)
- **Chemicals:** Propidium Iodide (MESH:D011419)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** CaSki — Homo sapiens (Human), Human papillomavirus-related cervical squamous cell carcinoma, Cancer cell line (CVCL_1100), BALB/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184), C33A — Homo sapiens (Human), Human papillomavirus-independent cervical squamous cell carcinoma, Cancer cell line (CVCL_1094), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11898548/full.md

---
Source: https://tomesphere.com/paper/PMC11898548